PMID: 8610832Mar 1, 1996Paper

Fluvoxamine alone in the treatment of delusional depression

The American Journal of Psychiatry
F GattiE Smeraldi

Abstract

The aim of this study was to evaluate the efficacy of fluvoxamine in the treatment of delusional depression. Fifty-nine inpatients who met the DSM-III-R criteria for major depression with psychotic features were treated with fluvoxamine for 6 weeks. Patients were assessed at baseline and weekly thereafter with the Hamilton Depression Rating Scale and the Dimensions of Delusional Experience rating scale. Of the 57 subjects completed the trial, 84.2% (N=48) recovered. The index episodes of the patients who did not respond to fluvoxamine were of significantly longer duration than those of the responders. Fluvoxamine has a response rate similar to that of the currently most efficacious treatments for delusional depression, including antidepressants plus antipsychotics and ECT.

Citations

Dec 21, 2000·Current Psychiatry Reports·B L O'NealM Trivedi
Jun 10, 2015·Journal of Receptor and Signal Transduction Research·Colin G Rousseaux, Stephanie F Greene
Dec 23, 2009·Annals of General Psychiatry·Tsutomu Furuse, Kenji Hashimoto
Jul 21, 2004·Psychiatry Research·Alessandro SerrettiEnrico Smeraldi
Aug 19, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Alessandro SerrettiDavid Rossini
Jun 2, 2009·Brain Research Reviews·Kenji Hashimoto
Jun 3, 1998·Journal of Affective Disorders·F BenedettiE Smeraldi
Apr 7, 2007·Journal of Clinical Psychopharmacology·Walter W van den BroekPeter Moleman
Dec 15, 2005·International Journal of Clinical Practice·J L Carrasco, C Sandner
Dec 12, 2001·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·B S MeyersG S Alexopoulos
Sep 29, 2001·Clinical Neuropharmacology·C Miodownik, V Lerner
Jul 3, 2004·Journal of Clinical Psychopharmacology·Anthony J RothschildGary D Tollefson
Oct 12, 2004·Pharmacogenetics·Alessandro SerrettiEnrico Smeraldi
Mar 18, 2008·Journal of Clinical Psychopharmacology·Tom K BirkenhagerJan A Bruijn
Sep 23, 2000·Journal of Clinical Psychopharmacology·J A Wheeler VegaP J Tyson
Jan 8, 1999·Acta Psychiatrica Scandinavica·A SerrettiE Smeraldi
Sep 15, 2005·Journal of Clinical Psychopharmacology·David RossiniRaffaella Zanardi
Feb 10, 2006·Expert Review of Neurotherapeutics·Pinhas N DannonMoshe Kotler
Mar 15, 2006·Psychopathology·Juan Pablo LucchelliGilles Bertschy
Jul 29, 2008·Harvard Review of Psychiatry·Hesham M Hamoda, David N Osser
May 16, 2009·Journal of Pharmacological Sciences·Sandra VezmarMilena Pokrajac
Jun 13, 2009·Nordic Journal of Psychiatry·Christina M DordingDavid Mischoulon
Dec 31, 1997·Journal of Clinical Psychopharmacology·R W Pies
Aug 5, 2020·Expert Opinion on Therapeutic Targets·James Michael BrimsonTewin Tencomnao
Aug 1, 1998·European Psychiatry : the Journal of the Association of European Psychiatrists·R Licht, P Kassow
Nov 10, 1998·Journal of Psychopharmacology·P J Goodnick, B J Goldstein
May 7, 1999·Journal of Geriatric Psychiatry and Neurology·B H Mulsant, B G Pollock
Jun 7, 2006·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Audrey R TyrkaLinda L Carpenter
Mar 8, 2011·Expert Opinion on Therapeutic Targets·Teruo HayashiTsung-Ping Su
Apr 8, 2015·Fundamental & Clinical Pharmacology·Auriana S VasconcelosFrancisca C F de Sousa
May 29, 2015·Acta Psychiatrica Scandinavica·S D ØstergaardB S Meyers
Apr 23, 2019·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·G P KostyukI V Reverchuk
Sep 21, 2002·Biological Psychiatry·Joseph K BelanoffAlan F Schatzberg
Apr 23, 2003·Biological Psychiatry·Anthony J Rothschild

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here